Cold atmospheric plasma sensitizes head and neck cancer to chemotherapy and immune checkpoint blockade therapy

Wang, Yanhong; Mang, Xinyu; Li, Danni; Wang, Zhao; Chen, Yiliang; Cai, Zhenyu; Tan, Fei

doi:10.1016/j.redox.2023.102991

Cited by 9 publications

(7 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22 Previously, SGLT2I was proposed as an potential anti-tumour agents since sodium-glucose cotransporter 2 was over-expressed in multiple tumour models, including head and neck cancer. 23, 24 In this study, we found that SGLT2I was associated with lower risk of NPC compared to DPP4I.…”

Section: Discussionmentioning

confidence: 51%

Nasopharyngeal Carcinoma and Head and Neck Cancer in Patients with Type-2 Diabetes Mellitus receiving SGLT2I, DPP4I or GLP1a: A population-based cohort study

Li,

Chou,

Mak

et al. 2024

Preprint

View full text Add to dashboard Cite

Introduction: Nasopharyngeal carcinoma (NPC) remains endemic in Asian regions, which risk factors were distinct from other head and neck (H&N) cancers. Anti-diabetic drugs has been proposed to reduce the risk of NPC. The associations between sodium glucose cotransporter 2 inhibitors (SGLT2I) versus dipeptidyl peptidase-4 inhibitors (DPP4I) and the risks of NPC and H&N cancer amongst type-2 diabetes mellitus (T2DM) patients remains unknown. Method: This was a retrospective population-based cohort study including T2DM patients treated with either SGLT2I or DPP4I between 1st January 2015 and 31st December 2019 in Hong Kong. The primary outcome was new-onset NPC and other H&N cancer. The secondary outcome was cancer-related mortality. Propensity score matching (1:1 ratio) was performed using the nearest neighbour search. Multivariable Cox regression was applied to identify significant predictors. Results: This cohort included 75,884 patients with T2DM, amongst whom 28,778 patients were on SGLT2I and 47,106 patients were on DPP4I. After matching (57556 patients), 106 patients developed NPC (0.18%), and 50 patients developed H&N cancer (0.08%). Compared to DPP4I, SGLT2I was associated with significantly lower risks of NPC (Hazard ratio [HR]: 0.41; 95% Confidence interval [CI]: 0.21-0.81) but not H&N cancer (HR: 1.00; 95% CI: 0.26-3.92) after adjustments. The result remained significant regardless of demographics and obesity. The association remained consistent in different risk models, matching approaches, and the sensitivity analysis. Conclusion: This study provides real-world evidence that SGLT2I was associated with lower risks of NPC, but not H&N cancer compared to DPP4I after adjustments amongst T2DM patients.

show abstract

Section: Discussionmentioning

confidence: 51%

Nasopharyngeal Carcinoma and Head and Neck Cancer in Patients with Type-2 Diabetes Mellitus receiving SGLT2I, DPP4I or GLP1a: A population-based cohort study

Li,

Chou,

Mak

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Inhibiting HO1 activity or Nrf2/HO1 gene silencing results in significantly greater apoptosis by CP [123]. Therefore, Nrf2/HO1 inhibition and CP adjunct therapy could synergise as a cancer therapy, similar to HO1 inhibition improving conventional chemo/radiotherapy and reducing tumour growth [173], or synergistic activity of CP with chemo/radiotherapy in vitro and in vivo [124,130,[174][175][176][177][178][179][180]. Unfortunately, the absence of clinically safe HO1 inhibitors currently precludes testing, but may be grounds for future clinical research.…”

Section: Keap1-nrf2-antioxidant Response Pathwaysmentioning

confidence: 99%

“…Regardless, both of these studies showed that CP induced JNK and p38 activity to slow tumour growth, but CP therapy alone was not effective enough to halt tumour progression. Fortunately, mouse xenografted tumour models have shown that combination therapy of CP/PAL and chemotherapeutic drugs can synergistically reduce tumour growth rate and even lead to tumour size reduction [124,130,177,179,180]. However, more animal models that test adjunct CP treatment with chemotherapy against progressive tumours are warranted to determine parameters for CP-augmenting chemotherapies before progressing to clinical trials.…”

Section: Mapk Inducing Cancer Cell Deathmentioning

confidence: 99%

Comparing Redox and Intracellular Signalling Responses to Cold Plasma in Wound Healing and Cancer

Abdo,

Kopecki

2024

Preprint

View full text Add to dashboard Cite

Cold plasma (CP) is an ionised gas containing excited molecules and ions, radicals, free electrons, and emits electric fields and UV radiation. CP is potently antimicrobial and can be applied safely to biological tissue, birthing the field of plasma medicine. Reactive oxygen and nitrogen species (RONS) produced by CP affect biological processes directly or indirectly via the modification of cellular lipids, proteins, DNA, and intracellular signalling pathways. CP can be applied at lower levels for oxidative eustress to activate cell proliferation, motility, migration, and antioxidant production in normal cells, mainly potentiated by the unfolded protein response, Nrf2-activated antioxidant response element and PI3K/Akt pathway, which also activates NFκB. At higher CP exposures, inactivation, apoptosis and autophagy of malignant cells can occur via degradation of PI3K/Akt and MAPK-dependent and -independent activation of the master tumour suppressor p53, leading to caspase-mediated cell death. These opposing responses validate a hormesis approach to plasma medicine. Clinical applications of CP are becoming increasingly realised in wound healing, while clinical effectiveness in tumours is currently coming to light. This review will outline advances in plasma medicine and compare the main redox and intracellular signalling responses to CP in wound healing and cancer.

show abstract

“…Inhibiting HO1 activity or Nrf2/HO1 gene silencing results in significantly greater apoptosis by CP [138]. Therefore, Nrf2/HO1 inhibition and CP adjunct therapy could synergise as a cancer therapy, similar to HO1 inhibition improving conventional chemo/radiotherapy and reducing tumour growth [187], or synergistic activity of CP with chemo/radiotherapy in vitro and in vivo [139,145,[188][189][190][191][192][193][194]. Unfortunately, the absence of clinically safe HO1 inhibitors currently precludes testing, but may be grounds for future clinical research.…”

Section: Keap1-nrf2-antioxidant Response Pathwaysmentioning

confidence: 99%

“…Regardless, both of these studies showed that CP induced JNK and p38 activity to slow tumour growth, but CP therapy alone was not effective enough to halt tumour progression. Fortunately, mouse xenografted tumour models have shown that combination therapy of CP/PAL and chemotherapeutic drugs can synergistically reduce tumour growth rate and even lead to tumour size reduction [139,145,191,193,194]. However, more animal models that test adjunct CP treatment with chemotherapy against progressive tumours are warranted to determine parameters for CP-augmenting chemotherapies before progressing to clinical trials.…”

Section: Mapk Inducing Cancer Cell Deathmentioning

confidence: 99%

Comparing Redox and Intracellular Signalling Responses to Cold Plasma in Wound Healing and Cancer

Abdo,

Kopecki

2024

CIMB

View full text Add to dashboard Cite

Cold plasma (CP) is an ionised gas containing excited molecules and ions, radicals, and free electrons, and which emits electric fields and UV radiation. CP is potently antimicrobial, and can be applied safely to biological tissue, birthing the field of plasma medicine. Reactive oxygen and nitrogen species (RONS) produced by CP affect biological processes directly or indirectly via the modification of cellular lipids, proteins, DNA, and intracellular signalling pathways. CP can be applied at lower levels for oxidative eustress to activate cell proliferation, motility, migration, and antioxidant production in normal cells, mainly potentiated by the unfolded protein response, the nuclear factor-erythroid factor 2-related factor 2 (Nrf2)-activated antioxidant response element, and the phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) pathway, which also activates nuclear factor-kappa B (NFκB). At higher CP exposures, inactivation, apoptosis, and autophagy of malignant cells can occur via the degradation of the PI3K/Akt and mitogen-activated protein kinase (MAPK)-dependent and -independent activation of the master tumour suppressor p53, leading to caspase-mediated cell death. These opposing responses validate a hormesis approach to plasma medicine. Clinical applications of CP are becoming increasingly realised in wound healing, while clinical effectiveness in tumours is currently coming to light. This review will outline advances in plasma medicine and compare the main redox and intracellular signalling responses to CP in wound healing and cancer.

show abstract

Cold atmospheric plasma sensitizes head and neck cancer to chemotherapy and immune checkpoint blockade therapy

Cited by 9 publications

References 85 publications

Nasopharyngeal Carcinoma and Head and Neck Cancer in Patients with Type-2 Diabetes Mellitus receiving SGLT2I, DPP4I or GLP1a: A population-based cohort study

Nasopharyngeal Carcinoma and Head and Neck Cancer in Patients with Type-2 Diabetes Mellitus receiving SGLT2I, DPP4I or GLP1a: A population-based cohort study

Comparing Redox and Intracellular Signalling Responses to Cold Plasma in Wound Healing and Cancer

Comparing Redox and Intracellular Signalling Responses to Cold Plasma in Wound Healing and Cancer

Contact Info

Product

Resources

About